Since the US Food and Drug Administration introduced the accelerated approval program in 1992, the agency has granted more than 250 approvals under this expedited pathway. The program has brought a number of important therapies to market earlier than would have been expected under the regular review process, including cancer immunotherapies.
However, despite the high-profile failure of several confirmatory trials for Genentech, Inc. ’s PD-L1 inhibitor Tecentriq (atezolizumab), Merck & Co., Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?